Translational Development Acquisition Corp. (TDACU) Stock Price & Analysis
Translational Development Acquisition Corp. (TDACU) rose 0.00% to USD 11.55 as of July 25, 2026 at 09:52 UTC, according to Nexqual real-time market data.
TDACU last closed at USD 11.55; the session ranged USD 11.55–11.55 on volume of 100 shares. Market capitalization is —, with a 52-week range of USD 10.31–17.29 (NGM). Source: Nexqual, July 25, 2026 at 09:52 UTC.
Key Statistics (as of July 25, 2026 at 09:52 UTC)
| Price | USD 11.55 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 11.55 |
| Open | USD 11.55 |
| Day Range | USD 11.55 – 11.55 |
| 52-Week Range | USD 10.31 – 17.29 |
| Volume | 100 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (TDACU)
Nexqual's technical model rates TDACU "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 09:52 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.38 (neutral) |
| vs SMA50 | Below (USD 11.67) |
| MACD | -0.03 (negative) |
Analyst Ratings (TDACU)
Wall Street analysts rate TDACU "None", per Nexqual as of July 25, 2026 at 09:52 UTC.
| Consensus Rating | None |
|---|
Earnings (TDACU)
Source: Nexqual, July 25, 2026 at 09:52 UTC.
Financials & Fundamentals (TDACU)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $24,630 |
| Total Debt | $500,000 |
| Free Cash Flow | $-352,611 |
Source: Nexqual, July 25, 2026 at 09:52 UTC.
Financial Health Score (TDACU)
Nexqual rates Translational Development Acquisition Corp.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $25K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$682K |
| Efficiency | Mixed — No data |
Ownership (TDACU)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +5.55% |
| Float | 15.95M |
Source: Nexqual, July 25, 2026 at 09:52 UTC.
Leadership (TDACU)
Translational Development Acquisition Corp. is led by Michael M. B. Hoffman (age 75), Chairman of the Board & CEO, per Nexqual as of July 25, 2026 at 09:52 UTC.
| Chairman of the Board & CEO | Michael M. B. Hoffman (age 75) |
|---|---|
| Chief Financial Officer | Avi C. Das |
Major Backers & Investors (TDACU)
Notable institutional backers of Translational Development Acquisition Corp. include Calamos Advisors LLC, CALAMOS INVESTMENT TRUST/IL-Calamos Market Neutral Income Fund, Shaw D.E. & Co., Inc., according to Nexqual as of July 25, 2026 at 09:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Calamos Advisors LLC | 2.5% |
| CALAMOS INVESTMENT TRUST/IL-Calamos Market Neutral Income Fund | 2.5% |
| Shaw D.E. & Co., Inc. | 2.33% |
| Yakira Capital Management, Inc. | 0.4% |
Source: Nexqual, July 25, 2026 at 09:52 UTC.
From Translational Development Acquisition Corp.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Translational Development Acquisition Corp. does not have significant operations.
- The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TDACW | Trident Acquisitions Corp. | USD 1.77 | ▲ 15.69% |
| LFACU | Leapfrog Acquisition Corporatio | USD 10.14 | ▲ 0% |
| TDAC | Translational Development Acqui | USD 10.74 | ▼ 0.05% |
| SOHOB | Sotherly Hotels Inc. | USD 1 | ▼ 88.37% |
| HCACU | Hall Chadwick Acquisition Corp. | USD 10.3 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:52 UTC. This page is informational and not investment advice.